bluuebunny/crossref_metadata_2025_split huggingface dataset:
What Helps? Mothers' and Children's Experiences of Community‐Based Early Intervention Programmes for Domestic Violence
Authors: McCarry Melanie , Radford Lorraine , Baker Victoria 
Published: February 2021

Early help or early intervention is increasingly recommended for safeguarding children living with domestic violence, but little is known about what is effective. This article discusses findings from an evaluation of a pioneering early help service in North West England. This new service aimed to improve the safety and wellbeing of families (mothers and children) who were assessed as below the level of ‘high risk’ domestic violence and below the threshold for a child protection order. Between January 2014 and March 2015, families (473 mothers and 541 children) were identified within multiagency safeguarding hubs and referred to the early help service. The service that emerged was somewhat different to the service expected. This article discusses findings from qualitative data gathered from 39 participants (mothers, children and service providers) involved in the programme. Three main issues emerged as themes from the interviews: the benefits of having any service at all for children living with domestic violence who slip off the agendas of professionals working with child protection and high‐risk domestic violence; the importance of flexibility of key worker‐led service delivery; and the suitability of current group work and therapeutic models for meeting the varied needs of families affected by domestic violence.Key Practitioner Messages

Children, mothers and service providers reported both a perceived need for early help and a positive impact from domestic violence early help services on child health and emotional wellbeing.
The ability of services to flex their delivery model in response to the needs of families is important for supporting engagement of, and fostering a sense of control for, families receiving support.
Confidentiality, reliability, respect and trust are key factors in developing an effective key worker‐family relationship.
‘Discusses findings from an evaluation of a pioneering early help service in North West England’
Sociability and interdependent self‐construal on consumer choice for group: A moderated mediation model
Authors: Li Zhen , Choi Soochan , Forrest Jeffrey Yi‐Lin 
Published: February 2021

AbstractIn joint consumptions, people often make consumption decisions for their respective groups, where chosen products or services are jointly shared by the members of their groups. Although the phenomena of joint consumptions appear commonly in real life, the literature of consumer behaviors has mainly focused on choices for the self instead of choices for others. This paper focuses on identifying the influence of personality on consumer choices for others. Specifically, it studies the relationship between sociability and consumption choice for a group by examining the mediation role of sensemaking process (i.e., information and feedback seeking) and the moderated mediation role of interdependent self‐construal. Our results show that individuals high on sociability are more likely to engage in group‐oriented consumption decision making, while obtaining social satisfaction; such effects tend to be achieved via information and feedback seeking, as a channel of sensemaking. And, the influence of sensemaking is stronger for individuals who are low in interdependent self‐construal. This research contributes to the consumer‐behavior literature by examining individual differences and provides practical insights for managers, decision makers and marketers.
Addressing the issue of “frequent flyers” post‐PCI
Authors: Vetrovec George W. 
Published: February 2021

Key Points
The frequency of multiple readmissions increase between 30 and180 days post‐index PCI associated with significant patient morbidity and cost.
Factors associated with multiple readmissions include patient clinical attributes and social factors.
Detailed assessment of clinical management coupled with addressing social risk represent future opportunities to improve patient outcomes and reduce cost.
Epitaph for bare‐metal stents: Unlearning is hard to do
Authors: Gilchrist Ian C. 
Published: February 2021

Key Points
Use of bare metal stents (BMS) saw a significant decline between 2013 and 2017 across 18 medical centers in Italy.
Indications for BMS most frequently included perceived risk of thrombosis during STEMI therapy or bleeding in the elderly or others from prolonged antiplatelet therapy despite information that was available to the contrary.
Persistent use of BMS represents an example of the problem of unlearning old information so that new and better practice patterns can be incorporated into practice.
PCI in TAVR patients: Timing isn't everything
Authors: Reilly John P. , Parikh Puja B. 
Published: February 2021

Key Points
Approximately 10% of patients referred for transcatheter aortic valve replacement (TAVR) undergo percutaneous coronary intervention (PCI), with over 85% receiving pre‐TAVR PCI and the remaining undergoing PCI either at the time of or following TAVR.
In patients undergoing TAVR and PCI, adverse events were higher in patients on warfarin and lower in patients with prior coronary artery bypass graft (CABG) surgery, higher body mass index, or those taking a statin.
No significant difference in rates of MACCE, mortality, or stroke at follow‐up were noted between patients who received PCI prior to TAVR and those who received PCI on day of or following TAVR in both the matched and unmatched populations.
Nine‐monthangiographic and2‐yearclinical outcomes of theRECOVERYtrial: A randomized study of the biodegradable polymersirolimus‐eluting COMBO dual‐therapystent versus apolymer‐free sirolimus‐elutingstent in Chinese patients
Authors: Tao Ling , Li Zhanquan , Yin Zhiyong , Lin Wenhua , Liu Yin , Li Hui , Yu Bo , Li Wei , Xu Bo ,   The RECOVERY Trial Investigators
Published: February 2021

AbstractObjectivesWe evaluated the safety and efficacy of the novel dual‐therapy sirolimus‐eluting and endothelial progenitor cell (EPC) capture COMBO stent.Background(Very) late stent thrombosis (ST) and neo‐atherosclerosis limit the performance of drug‐eluting stents. The capture of EPCs accelerates stent re‐endothelialization, thereby potentially decreasing the risk of restenosis and ST.MethodsIn total, 440 patients with de novo lesions in native coronary arteries were randomized (1:1) to either receive the COMBO stent (n = 220) or Nano polymer‐free sirolimus‐eluting stent (n = 220). The primary endpoint was the 9‐month angiographic in‐segment late lumen loss (LLL). Secondary endpoints included target lesion failure (TLF), a patient‐oriented composite endpoint (PoCE), and ST.ResultsAt 9 months, the COMBO in‐segment LLL (0.29 ± 0.46 mm) was non‐inferior to that of the Nano comparator stent (0.31 ± 0.44 mm;pnon‐inferiority < .0001). Clinical outcomes were also similar between the COMBO and Nano stents, with TLF rates of 9.3% and 7.9% (p= .61) at 12 months, and 9.4% and 8.0% (p= .62) at 24 months, respectively. The PoCE rate was 14.8% and 10.6% (p= .19) at 12 months, and 16.0% and 11.3% (p= .16) at 24 months, respectively. Ischemia‐driven target lesion revascularization rates were 6.0% and 3.7% (p= .26) at 12 months, and 6.2% and 3.8% (p= .26) at 24 months, respectively. No case of ST occurred in either group.ConclusionsThe RECOVERY trial has shown the COMBO stent was effective, meeting the primary non‐inferiority angiographic endpoint, and safe, with an overall low rate of clinical events in both stent groups, including no ST for up to 2 years.
IQR CUSUM charts: An efficient approach for monitoring variations in aquatic toxicity
Authors: Hussain Shahid , Sun Mei , Mahmood Tahir , Riaz Muhammad , Abid Muhammad 
Published: February 2021

AbstractToxicant testing is a major component of the environmental solution testing program. This test system aims to evaluate the sensitivity of the test species, evaluate comparability between laboratory test results, and classify possible variability sources such as healthy organisms, organism batches, laboratory water, and food quality changes. For the continuous assessment of sensitivity and accuracy of laboratory toxicity tests, control charts are often used. The cumulative sum (CUSUM) charting structure is a popular monitoring tool that is often used due to its outstanding ability in recognizing small‐to‐moderate unusual changes in process parameters. The CUSUM control charts have now been widely accepted/applied for monitoring the process dispersion under the assumption that the process does not have outliers. In practice, most of the processes have outliers. Therefore, the use of the interquartile range (IQR) as a plotting statistic is an attractive choice for dispersion monitoring. Hence, in this study, the CUSUM control chart with auxiliary information‐based IQR estimators is proposed and employed to monitor dispersion or variation in the variable LC50 by using quantitative structure–activity relationship (QSAR) aquatic toxicity data set. The proposed IQR‐CUSUM charts are compared to its counterparts by using a variety of main output run‐length functions, such as average run length (ARL), standard deviation of run length (SDRL), and extra quadratic loss (EQL), derived from the distribution of run‐length. Further, results revealed that the proposed CUSUM charts have better detection ability as compared to existing counterpart charts, both in theoretical and practical considerations.
A grouped beta process model for multivariate resting‐state EEG microstate analysis on twins
Authors: Hart Brian , Malone Stephen , Fiecas Mark 
Published: February 2021

AbstractEEG microstate analysis investigates the collection of distinct temporal blocks that characterize the electrical activity of the brain. Brain activity within each microstate is stable, but activity switches rapidly between different microstates in a nonrandom way. We propose a Bayesian nonparametric model that concurrently estimates the number of microstates and their underlying behaviour. We use a Markov switching vector autoregressive (VAR) framework, where a hidden Markov model (HMM) controls the nonrandom state switching dynamics of the EEG activity and a VAR model defines the behaviour of all time points within a given state. We analyze the resting‐state EEG data from twin pairs collected through the Minnesota Twin Family Study, consisting of 70 epochs per participant, where each epoch corresponds to 2 s of EEG data. We fit our model at the twin pair level, sharing information within epochs from the same participant and within epochs from the same twin pair. We capture within twin‐pair similarity, using an Indian buffet process, to consider an infinite library of microstates, allowing each participant to select a finite number of states from this library. The state spaces of highly similar twins may completely overlap while dissimilar twins could select distinct state spaces. In this way, our Bayesian nonparametric model defines a sparse set of states that describe the EEG data. All epochs from a single participant use the same set of states and are assumed to adhere to the same state switching dynamics in the HMM model, enforcing within‐participant similarity.
Nodal staging convergence for HPV− and HPV+ oropharyngeal carcinoma
Authors: Ho Allen S. , Luu Michael , Kim Sungjin , Tighiouart Mourad , Mita Alain C. , Scher Kevin S. , Mallen‐St. Clair Jon , Walgama Evan S. , Lin De‐Chen , Nguyen Anthony T. , Zumsteg Zachary S. 
Published: February 2021

BackgroundModern disease staging systems have restructured human papillomavirus (HPV)‐negative (HPV−) and HPV‐positive (HPV+) oropharyngeal carcinoma (OPC) into distinct pathologic nodal systems. Given that quantitative lymph node (LN) burden is the dominant prognostic factor in most head and neck cancers, we investigated whether HPV− and HPV+ OPC warrant divergent pathologic nodal classification.MethodsMultivariable Cox regression models of OPC surgical patients identified via U.S. cancer registry data were constructed to determine associations between survival and nodal characteristics. Nonlinear associations between metastatic LN number and survival were modeled with restricted cubic splines. Recursive partitioning analysis (RPA) was used to derive unbiased nodal schema.ResultsMortality risk escalated continuously with each successive positive LN in both OPC subtypes, with analogous slope. Survival hazard increased by 18.5% (hazard ratio [HR], 1.19 [95% CI, 1.16‐1.21]; P < .001) and 19.1% (HR, 1.19 [95% CI, 1.17‐1.21]; P < .001), with each added positive LN for HPV− and HPV+ OPC, respectively, up to identical change points of 5 positive LNs. Extranodal extension (ENE) was an independent predictor of HPV− OPC (HR, 1.55 [95% CI, 1.20‐1.99]; P < .001) and HPV+ OPC (HR 1.73 [95% CI, 1.36‐2.20]; P < .001) mortality. In RPA for both diseases, metastatic LN was the principal nodal covariate driving survival, with ENE as a secondary determinant. Given the similarities across analyses, we propose a concise, unifying HPV−/HPV+ OPC pathologic nodal classification schema: N1, 1‐5 LN+/ENE−; N2, 1‐5 LN+/ENE+; N3, >5 LN+.ConclusionHPV− and HPV+ OPC exhibit parallel relationships between nodal characteristics and relative mortality. In both diseases, metastatic LN number represents the principal nodal covariate governing survival, with ENE being an influential secondary element. A consolidated OPC pathologic nodal staging system that is based on these covariates may best convey prognosis.Lay Summary

The current nodal staging system for oropharyngeal carcinoma (OPC) has divided human papillomavirus (HPV)‐negative (HPV−) and HPV‐positive (HPV+) OPC into distinct systems that rely upon criteria that establish them as separate entities, a complexity that may undermine the core objective of staging schema to clearly communicate prognosis.

Our large‐scale analysis revealed that HPV− and HPV+ pathologic nodal staging systems in fact mirror each other. Multiple analyses produced conspicuously similar nodal staging systems, with metastatic lymph node number and extranodal extension delineating the highest risk groups that shape prognosis.

We propose unifying HPV− and HPV+ nodal systems to best streamline prognostication and maximize staging accuracy.
SARS‐CoV‐2 nosocomial infection: Real‐world results of environmental surface testing from a large tertiary cancer center
Authors: Shah Mansi R. , Jan Imraan , Johns Jeremy , Singh Kuldip , Kumar Pallavi , Belarmino Norma , Saggiomo Kara J. , Hayes Carolyn , Washington Kimyatta , Toppmeyer Deborah L. , Haffty Bruce G. , Libutti Steven K. , Evens Andrew M. 
Published: February 2021

BACKGROUNDDespite consensus guidelines, concern about severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) transmission has dissuaded patients with cancer from seeking medical care. Studies have shown that contaminated surfaces may contain viable virus for up to 72 hours in laboratory settings. The purpose of this study was to investigate contamination of SARS‐CoV‐2 on commonly used environmental surfaces in a tertiary cancer care center.METHODSThis study evaluated the incidence of SARS‐CoV‐2 viral RNA in high‐touch outpatient and inpatient cancer center spaces. Surfaces were tested over a 2‐week period after patient or staff exposure but before scheduled disinfection services according to the World Health Organization protocols for coronavirus disease 2019 (COVID‐19) surface sampling. Samples were analyzed via reverse transcriptase–polymerase chain reaction for the presence of SARS‐CoV‐2 RNA.RESULTSTwo hundred four environmental samples were obtained from inpatient and outpatient oncology clinics and infusion suites, and they were categorized as 1) public areas, 2) staff areas, or 3) medical equipment. One hundred thirty surfaces from 2 outpatient hematology and oncology clinics and 36 surfaces from an inpatient leukemia/lymphoma/chimeric antigen receptor T‐cell unit were examined, and all 166 samples were negative for SARS‐CoV‐2. One of 38 samples (2.6%) from COVID‐19+ inpatient units was positive. Altogether, the positive test rate for SARS‐CoV‐2 RNA across all surfaces was 0.5% (1 of 204).CONCLUSIONSThis prospective, systematic quality assurance investigation of real‐world environmental surfaces, performed in inpatient and outpatient hematology/oncology units, revealed overall negligible detection of SARS‐CoV‐2 RNA when strict mitigation strategies against COVID‐19 transmission were instituted.LAY SUMMARY

The potential risks of nosocomial infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have deterred patients with cancer from seeking timely care despite consensus guidelines.

This study has found negligible rates of environmental contamination with SARS‐CoV‐2 across a multitude of commonly used surfaces in outpatient and inpatient hematology/oncology settings with adherence to strict infection control protocols.
Sharing and caring: The impact of social support on quality of life and health outcomes in hematopoietic stem cell transplantation
Authors: Amonoo Hermioni L. , Johnson P. Connor , Dhawale Tejaswini M. , Traeger Lara , Rice Julia , Lavoie Mitchell W. , Ufere Nneka N. , Longley Regina M. , Harnedy Lauren E. , Clay Madison A. , Topping Carlisle E. W. , DeFilipp Zachariah , Chen Yi‐Bin A. , El‐Jawahri Areej 
Published: February 2021

BackgroundSocial support is crucial for successful recovery after hematopoietic stem cell transplantation (HSCT) and has the potential to affect patient quality of life (QOL) and health outcomes. However, there are limited data on the relationship between a patient's perception of his or her social support and these outcomes.MethodsThe authors conducted a secondary analysis of 250 autologous and allogeneic HSCT recipients enrolled in 2 supportive care trials at Massachusetts General Hospital from April 2011 through February 2016. They assessed social support as a patient's perception of his or her social well‐being via the social well‐being subscale of the Functional Assessment of Cancer Therapy. The authors used multivariate regression analyses to examine the relationship between pretransplant social well‐being and QOL (Functional Assessment of Cancer Therapy–Treatment Outcome Index), psychological distress (Hospital Anxiety and Depression Scale), posttraumatic stress disorder [PTSD] symptoms (PTSD Checklist), fatigue (Functional Assessment of Cancer Therapy–Fatigue), and health care utilization (hospitalizations and days alive and out of the hospital) 6 months after HSCT.ResultsParticipants were on average 56.4 years old (SD, 13.3 years); 44% (n = 110) and 56% (n = 140) received autologous and allogeneic HSCT, respectively. Greater pre‐HSCT social well‐being was associated with higher QOL (B = 0.10; 95% CI, 0.06‐0.13; P < .001), lower psychological distress (B = –0.21; 95% CI, –0.29 to –0.12; P < .001), and lower PTSD symptoms (B = –0.12; 95% CI, –0.19 to –0.06; P < .001). Pre‐HSCT social well‐being was not significantly associated with fatigue or health care utilization 6 months after HSCT.ConclusionsPatients with higher pre‐HSCT perceptions of their social support reported better QOL and lower psychological distress 6 months after HSCT. These findings underscore the potential for social support as a modifiable target for future supportive care interventions to improve the QOL and care of HSCT recipients.
Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies
Authors: Jeha Sima , Crews Kristine R. , Pei Deqing , Peyton Melissa , Panetta John C. , Ribeiro Raul C. , Zhao Xujie , Campbell Patrick , Metzger Monika L. , Yang Jun J. , Cheng Cheng , Pui Ching‐Hon , Bhojwani Deepa 
Published: February 2021

BackgroundA phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies.MethodsPatients younger than 22 years with second or greater relapsed or refractory acute leukemia or lymphoma after 2 or more prior regimens were eligible. With the rolling 6 design, participants received escalating doses of bendamustine (30, 40, or 60 mg/m2/d) in combination with clofarabine (40 mg/m2), etoposide (100 mg/m2), and dexamethasone (8 mg/m2) daily for 5 days. Optional pharmacokinetic studies were performed in cycle 1 on day 1 and day 5.ResultsSixteen patients were enrolled. Six patients were treated at the dose level of 30 mg/m2/d, 6 were treated at the dose level of 40 mg/m2/d, and 4 were treated at the dose level of 60 mg/m2/d. The dose‐limiting toxicity was prolonged myelosuppression. The combination was otherwise well tolerated. The recommended dose of bendamustine in this combination was 30 mg/m2/d for 5 days. Ten responses were observed after 1 cycle: 6 complete remissions, 1 durable minimal residual disease–negative complete remission without platelet recovery in a patient with early T‐cell precursor leukemia, and 3 partial remissions. Six patients proceeded to transplantation. The event‐free survival rate was 40.6% (95% confidence interval [CI], 17.5%‐63.7%) at 1 year and 33.9% (95% CI, 11.9%‐55.9%) at 3 years.ConclusionsBendamustine is well tolerated in combination with clofarabine, etoposide, and dexamethasone. The combination administered over 5 days is effective for multiple relapsed and refractory hematologic malignancies. This trial is registered with ClinicalTrials.gov (NCT01900509).Lay Summary

Improvements to the existing chemotherapy regimen are still needed for patients who relapse after targeted therapies and immunotherapies and for those who are not eligible for or have no access to such therapies.

A regimen combining cyclophosphamide, clofarabine, and etoposide has been used in relapsed and refractory pediatric patients with hematologic malignancies.

This study shows that substituting bendamustine for cyclophosphamide in combination with clofarabine and etoposide is safe and effective.